Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

South Africa: These 23 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "South Africa: These 23 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in South Africa?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: South Africa Patent 200,903,907
Patent Title: FUMARATE SALT OF (ALPHA S,BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in South Africa?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Africa Patent 200,903,601
Patent Title: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in South Africa?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: South Africa Patent 200,905,365
Patent Title: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in South Africa?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: South Africa Patent 200,905,621

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Africa?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Africa Patent 200,905,630
Patent Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Africa?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Africa Patent 200,905,630
Patent Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in South Africa?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: South Africa Patent 200,905,590
Patent Title: Pleuromutilin derivatives for the treatment of diseases mediated by microbes

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can INLYTA (axitinib) generic drug versions launch in South Africa?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: South Africa Patent 200,906,990

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Africa?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Africa Patent 200,907,710
Patent Title: NOVEL PHARMACEUICAL COMPOSITION

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in South Africa?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: South Africa Patent 200,907,511
Patent Title: Novel piperazine salts as D3/D2 antagonists

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in South Africa?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: South Africa Patent 200,907,168
Patent Title: An extended-release composition comprising a somatostatin derivative in microparticles

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in South Africa?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: South Africa Patent 200,907,940

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in South Africa?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: South Africa Patent 200,907,940

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in South Africa?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Africa Patent 200,907,928
Patent Title: SYNETHOC BILE ACID COMPOSITION, METHOD, AND PREPARATION

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can WINLEVI (clascoterone) generic drug versions launch in South Africa?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: South Africa Patent 201,100,133
Patent Title: ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in South Africa?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: South Africa Patent 201,000,874
Patent Title: Dhea compositions for treating menopause

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in South Africa?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: South Africa Patent 201,000,718
Patent Title: Radiopharmaceutical composition

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in South Africa?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: South Africa Patent 201,002,131
Patent Title: PROCESS FOR THE MANUFACTURE OF A PHARMACEUTICAL PRODUCT COMPRISING CITRIC ACID,MAGNESIUM OXIDE,POTASSIUM BICARBONATE AND SODIUM PICOSULFATE,PHARMACEUTICAL COMPOSITION COMPRISING GRANULES OBTAINED BY SUCH PROCESS AND INTERMEDIATE

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in South Africa?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: South Africa Patent 201,004,256
Patent Title: PHARMACEUTICAL COMPOSITIONS

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in South Africa?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Africa Patent 201,101,626
Patent Title: COMPOUNDS,COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in South Africa?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Africa Patent 201,203,779
Patent Title: COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in South Africa?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Africa Patent 201,101,626
Patent Title: COMPOUNDS,COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in South Africa?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Africa Patent 201,203,779
Patent Title: COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in South Africa?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: South Africa Patent 201,003,623
Patent Title: SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in South Africa?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: South Africa Patent 200,903,367
Patent Title: 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy) pyrimidine-based compounds and methods of their use

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

South Africa Branded and Generic Drug Markets: Regulatory Assessment, Patent Risk and Commercial Opportunities

Last updated: October 16, 2026

South Africa is the largest pharmaceutical market in sub-Saharan Africa and the region’s primary regulatory and distribution hub. Generics dominate public-sector volume and have a substantial position in private retail, while originator products retain value in specialty medicines, chronic therapies, hospital products, and biologics. The main commercial constraints are South Africa’s single-exit-price regime, extended SAHPRA registration timelines, public tender price pressure, currency volatility, and the absence of an effective patent-linkage system.

What is the size and structure of the South African pharmaceutical market?

South Africa has a two-channel medicines market:

Channel Main buyers Commercial characteristics
Public sector National and provincial health departments, state hospitals and clinics Centralized or coordinated tenders, high generic use, price-sensitive procurement
Private sector Pharmacies, hospitals, medical schemes, doctors and patients Brand competition, medical-aid reimbursement, pharmacy substitution and chronic-care demand

Private-sector medicines are generally distributed through wholesalers, pharmacies, dispensing doctors and private hospitals. Public-sector medicines are bought through tenders administered by national or provincial authorities, with supply reliability and local distribution capacity carrying material weight alongside price.

Market estimates differ by source because some reports include hospital products, vaccines, consumer health products and wholesale turnover while others measure manufacturer sales only. Public sources consistently identify South Africa as the dominant pharmaceutical market in sub-Saharan Africa, with annual sales measured in the tens of billions of rand. IQVIA has reported continued growth in pharmaceutical spending, driven by chronic diseases, private healthcare utilization, hospital products and specialty medicines (IQVIA, 2024).

Which therapeutic areas drive demand?

The strongest demand drivers are:

  • HIV and antiretroviral medicines
  • Hypertension, diabetes and cardiovascular products
  • Oncology medicines
  • Respiratory medicines
  • Central nervous system therapies
  • Vaccines and anti-infectives
  • Hospital injectables and critical-care products
  • Biosimilars and specialty biologics

South Africa has one of the world’s largest HIV treatment programs. The government’s HIV procurement system creates significant volume for antiretroviral manufacturers but imposes severe price and tender-compliance requirements. Private-sector growth is more attractive in oncology, diabetes, immunology, respiratory disease and specialty hospital products, where treatment complexity and reimbursement can support higher prices.

How do branded and generic medicines compete in South Africa?

Generics have a structural advantage in the public sector because government tenders prioritize cost, supply continuity and compliance. In private pharmacies, generic substitution is legally supported, although prescriber behavior, patient confidence, pharmacy economics and medical-scheme formularies affect actual substitution.

Originator brands retain stronger positions where:

  • The medicine has a narrow therapeutic index.
  • The product is a complex injectable or biologic.
  • Physicians prefer the originator based on clinical familiarity.
  • The product has a differentiated delivery system.
  • The medicine is prescribed in oncology, immunology or hospital care.
  • The originator has strong patient-support and adherence programs.
  • The generic market has limited manufacturing capacity.

A generic does not need to defeat the originator brand in every segment. A commercially viable launch may target public tenders, a narrow private formulary, hospital supply, or a single high-volume chronic indication.

What are the main advantages of generic manufacturers?

Generic companies benefit from:

  1. Lower research and development costs.
  2. Established active pharmaceutical ingredient suppliers.
  3. Bioequivalence pathways rather than full clinical development.
  4. Pharmacy substitution.
  5. Public-sector procurement preferences.
  6. Growing demand for lower-cost chronic medicines.
  7. Opportunities to supply branded generics under local or regional labels.

The principal risks are low tender margins, payment delays in some public channels, foreign-exchange exposure, manufacturing interruptions and competition from multinational and Indian suppliers.

Which companies are important in the South African market?

The market includes multinational originators, South African manufacturers, Indian generic companies and regional distributors. Important local or locally established participants include Aspen Pharmacare, Adcock Ingram, Cipla Medpro South Africa, Sanofi South Africa, Novartis, Roche, Pfizer, Johnson & Johnson, MSD, Viatris, Fresenius Kabi and other multinational and specialty suppliers.

Aspen has particular importance in manufacturing, sterile products and regional distribution. Adcock Ingram has a major private-sector and hospital presence. Indian suppliers compete through generic portfolios, contract manufacturing and local marketing authorization holders. Multinational companies concentrate on innovative medicines, vaccines, specialty products and selected high-value generics.

What is the South African regulatory status for medicines?

The South African Health Products Regulatory Authority, or SAHPRA, is the primary medicines regulator. The U.S. Food and Drug Administration has no approval authority in South Africa. FDA approval may support reliance, due diligence or regulatory credibility, but it does not replace SAHPRA authorization.

The principal legal framework is the Medicines and Related Substances Act 101 of 1965 and its regulations. SAHPRA regulates:

  • New chemical entities
  • Generic medicines
  • Biological medicines
  • Biosimilars
  • Vaccines
  • Complementary medicines
  • Clinical trials
  • Manufacturing and distribution sites
  • Pharmacovigilance
  • Advertising and promotion

What registration pathway applies to generic drugs?

A conventional generic normally requires:

  • Pharmaceutical and quality documentation
  • Evidence of pharmaceutical equivalence
  • Bioequivalence data where applicable
  • Stability data
  • Good manufacturing practice evidence
  • Labeling and packaging materials
  • A South African applicant or local regulatory representation
  • Compliance with SAHPRA administrative requirements

Biological products and biosimilars face a more demanding evidence package. The applicant must establish similarity in quality, safety and efficacy to a reference product, with an appropriate analytical, nonclinical and clinical package.

SAHPRA has adopted regulatory reliance and work-sharing mechanisms to improve review efficiency. Applicants may use assessments by trusted reference agencies or regional regulatory mechanisms where accepted by SAHPRA. The practical value of reliance depends on product type, dossier quality, local requirements and SAHPRA capacity.

What are the main regulatory delays?

The largest regulatory challenge has been the accumulation of registration and variation backlogs. Delays have affected commercial launch planning, product renewals, manufacturing changes, line extensions and generic competition. SAHPRA has implemented reforms, including reliance pathways, risk-based reviews, digitization and collaboration with international agencies, but applicants still need to build extended regulatory lead times into launch plans (SAHPRA, 2024).

What is the Orange Book status of South African medicines?

South Africa does not have a U.S.-style Orange Book system that links approved medicines, listed patents and generic approval dates. There is no direct South African equivalent to the FDA Orange Book certification process.

Consequences include:

  • Patent status is not centrally connected to the marketing authorization database.
  • Generic applicants generally do not file a U.S.-style Paragraph IV certification.
  • SAHPRA does not make a formal patent-infringement determination as part of routine registration.
  • Patent disputes are handled through private litigation in the High Court.
  • Freedom-to-operate analysis must combine patent-register searches, family analysis, expiry calculations and litigation review.

A South African marketing authorization does not itself eliminate patent risk. A company may obtain regulatory approval and still face an infringement claim if it launches before relevant patent expiry.

When do South African drug patents lose exclusivity?

A standard South African patent generally expires 20 years from its effective filing date, subject to statutory requirements and the specific patent record. South Africa does not provide the same standardized patent-term-extension framework found in the United States or European Union for regulatory delay.

Exclusivity element South African position
Standard patent term Generally 20 years from filing
Patent linkage No effective Orange Book-style linkage
Paragraph IV process No U.S.-style statutory process
Regulatory review exception Section 69A of the Patents Act provides an exception for acts connected with obtaining regulatory approval
Data exclusivity No broad U.S.-style new-molecule data-exclusivity period
Supplementary protection certificate No general EU-style SPC regime
Compulsory licensing Available in principle under the Patents Act, although commercially significant compulsory-license use remains limited
Patent litigation forum South African High Court, typically the Commissioner of Patents

Section 69A is commercially important because it permits certain activities needed to generate and submit regulatory information before patent expiry. The provision does not create a general right to commercially launch an infringing product before the patent expires.

How many patents typically cover a medicine?

A product may be covered by several patent categories:

  • Composition-of-matter patents
  • Salt, polymorph and crystalline-form patents
  • Formulation patents
  • Dosage and dosing-regimen patents
  • Combination-therapy patents
  • Device or delivery-system patents
  • Manufacturing-process patents
  • Method-of-treatment patents

South African patent strength depends on whether the relevant patent was validly granted, remains in force, covers the proposed product and can withstand revocation or non-infringement arguments. South Africa’s historically non-examining patent system increases the importance of post-grant validity review. Patent claims are not necessarily substantively tested before grant in the manner used by the U.S. Patent and Trademark Office or the European Patent Office.

What patent litigation and Paragraph IV risks affect generic entry?

South Africa has no formal Paragraph IV notice process. A generic company may nevertheless face litigation if the originator believes launch, manufacture, importation, sale or process use infringes an unexpired patent.

Common dispute issues include:

  • Whether a formulation claim covers the generic product.
  • Whether a process patent applies to the supplier’s manufacturing route.
  • Whether a patent is invalid for lack of novelty or inventive step.
  • Whether the patent has expired.
  • Whether the generic product falls outside the claim scope.
  • Whether the originator can obtain an interim interdict.
  • Whether damages or a reasonable royalty is available.

Generic companies usually manage the risk through an early freedom-to-operate review, patent opposition or revocation strategy, non-infringement positions, alternative formulations, alternative manufacturing routes and settlement negotiations.

Patent litigation can delay launch even when the generic ultimately prevails. A launch strategy therefore must evaluate both legal merits and the likelihood of interim relief.

What formulation and method-of-use patents protect branded medicines?

Formulation patents are increasingly important after composition-of-matter protection expires. They may cover:

  • Extended-release tablets
  • Injectable depot formulations
  • Stabilized biologics
  • Specific excipient combinations
  • Abuse-deterrent formulations
  • Fixed-dose combinations
  • Transdermal or inhaled delivery systems
  • Device-enabled administration

Method-of-use patents may cover a patient population, treatment line, dosage schedule, biomarker-defined subgroup or combination with another therapy. Their commercial value depends on enforceability and the ability to identify or control the patented use in the market.

A generic company can reduce exposure by using a non-infringing label, removing a patented indication where legally and commercially practical, or developing a different formulation. These approaches require careful review of labeling, promotion, physician communication and supply-channel conduct.

What is the biosimilar opportunity in South Africa?

Biosimilars offer one of the strongest growth opportunities in South Africa’s high-cost medicine segment. The opportunity is supported by:

  • Public-sector budget pressure
  • Expiring biologic patents
  • Oncology and immunology demand
  • Hospital procurement
  • Medical-scheme cost containment
  • Regional export potential

The main barriers are regulatory complexity, reference-product requirements, pharmacovigilance obligations, cold-chain costs, physician confidence and limited interchangeability clarity. A biosimilar sponsor must also assess manufacturing patents, formulation patents, device claims and process patents.

Biosimilar launch risk is higher than conventional generic risk because clinical and analytical development costs are materially greater. Manufacturing quality and supply reliability can be as important as price.

What pricing rules affect branded and generic drugs?

South Africa uses a single-exit-price, or SEP, system. Manufacturers and importers establish a regulated single exit price, with separate permitted logistics and dispensing components. The framework limits conventional discounting and requires annual price increases to comply with government-approved limits (Department of Health, 2024).

Pricing consequences include:

  • Limited freedom to discount privately below the regulated SEP.
  • Strong pressure to maintain a competitive launch price.
  • Reduced flexibility for differentiated generic pricing.
  • Greater importance of formulary placement and distribution efficiency.
  • Risk that public tender prices do not translate into private-sector prices.

Public tenders may require prices below the level that is commercially sustainable in private distribution. Companies should separate tender economics from private-market economics and model inventory, freight, working capital, currency and service-level costs.

What licensing deals and market-entry structures are available?

The most practical entry models are:

Model Best suited to Main risk
Local marketing authorization holder Foreign generic or specialty company Dependence on local regulatory and commercial execution
Distribution agreement Established product with limited launch complexity Low control over pricing and promotion
In-licensing Local company seeking differentiated products Royalty burden and minimum-sales commitments
Contract manufacturing Products requiring local supply or tender eligibility Technology transfer and quality oversight
Co-promotion Specialty or hospital medicines Channel conflict and compliance controls
Local manufacturing joint venture Long-term public-sector or regional strategy Capital intensity and regulatory complexity

Licensing agreements should address SAHPRA registration ownership, patent responsibility, pharmacovigilance, recalls, tender authority, SEP control, minimum volumes, supply continuity, change control and regional rights. Local partners are particularly valuable where the foreign company lacks established pharmacy, hospital or government-procurement access.

What geographic coverage can South African approval support?

South African registration does not automatically authorize sale elsewhere in Africa. It can, however, support regional strategy because South Africa has a relatively developed regulatory system, sophisticated private healthcare infrastructure and an established distribution network.

Potential regional markets include:

  • Southern African Development Community countries
  • East African markets through separate national or regional procedures
  • Selected African procurement programs
  • Export markets requiring recognized GMP and regulatory documentation

Export expansion remains constrained by country-specific registration, foreign-exchange controls, logistics, tender rules and local representative requirements.

What generic launch scenarios are most likely?

Three launch scenarios are commercially realistic:

At-risk launch

The company launches before all patent disputes are resolved. This offers first-mover revenue but creates exposure to an interdict, damages and forced withdrawal. It is most appropriate where patent validity is weak and the commercial upside is substantial.

Day-one launch

The company obtains approval and launches promptly after the relevant patent expires. This is the lowest legal-risk model but requires early dossier filing, manufacturing readiness and channel preparation.

Delayed or settlement launch

The generic company settles with the originator or waits for litigation resolution. The agreement may include a launch date, supply arrangement, royalty, non-compete provisions or licensing rights. Settlement terms require competition-law review and careful drafting.

Revenue exposure is highest in chronic medicines, oncology, antiretrovirals, diabetes and cardiovascular products because recurring treatment and large patient populations amplify small price or market-share changes.

How strong is the South African patent estate compared with the regulatory estate?

The regulatory estate is improving but remains operationally constrained by review capacity and administrative backlog. The patent estate can be valuable for originators, but its enforceability is less predictable because patent validity is generally tested after grant and no Orange Book system organizes product-patent information.

For originators, the strongest protections usually combine:

  • A valid composition patent
  • A commercially meaningful formulation or device patent
  • Manufacturing know-how
  • Trademarks and brand recognition
  • Regulatory exclusivity where available
  • Supply contracts and hospital relationships

For generics, the strongest entry position combines a completed bioequivalence program, early SAHPRA filing, manufacturing redundancy, a documented freedom-to-operate opinion and a tender-ready supply chain.

Key Takeaways

  • South Africa is the leading pharmaceutical market in sub-Saharan Africa.
  • Generics dominate public-sector volume and compete strongly in private pharmacies.
  • Originators retain value in biologics, oncology, hospital products and differentiated formulations.
  • SAHPRA, not the FDA, controls South African medicine authorization.
  • South Africa has no Orange Book-style patent linkage or U.S.-style Paragraph IV process.
  • Standard patent protection generally lasts 20 years from filing.
  • Formulation, method-of-use, device and manufacturing patents can delay generic entry after compound-patent expiry.
  • Section 69A supports regulatory preparation before patent expiry but does not authorize infringing commercial launch.
  • SEP regulation and public tenders create substantial price pressure.
  • Biosimilars, specialty generics, hospital products and regional exports offer the strongest growth opportunities.
  • Market entry depends on regulatory execution, local distribution, tender capability, patent analysis and supply reliability.

FAQs

Does South Africa allow generic substitution at pharmacies?

Yes. Section 22F of the Medicines and Related Substances Act requires pharmacists to inform patients about generic alternatives and generally supports substitution, subject to statutory exceptions, prescriber instructions and patient choice.

Can a foreign pharmaceutical company sell directly in South Africa?

A foreign company generally needs an appropriate South African applicant, registration holder, importer, wholesaler and pharmacovigilance structure. Direct commercial activity without local regulatory and distribution compliance is not a viable launch model.

Are South African patents substantively examined before grant?

South Africa has historically operated a non-examining patent system. Patent validity can therefore become a major issue in opposition, revocation or infringement litigation after grant.

Can a generic medicine obtain SAHPRA approval before patent expiry?

Regulatory preparation and approval may be possible before patent expiry, subject to the applicable legal framework. Commercial launch remains subject to patent rights and infringement risk.

Are biosimilars automatically interchangeable with reference biologics in South Africa?

No automatic interchangeability assumption should be made. Biosimilar approval, substitution practice and procurement treatment depend on SAHPRA requirements, clinical evidence, product labeling and institutional or pharmacy policy.

References

Department of Health, Republic of South Africa. (2024). Single exit price adjustment and pharmaceutical pricing regulatory framework. Pretoria: National Department of Health.

IQVIA. (2024). The global use of medicines 2024: Outlook to 2028. IQVIA Institute for Human Data Science.

Republic of South Africa. (1965). Medicines and Related Substances Act 101 of 1965. Pretoria: Government Printer.

Republic of South Africa. (1978). Patents Act 57 of 1978. Pretoria: Government Printer.

South African Health Products Regulatory Authority. (2024). SAHPRA annual report 2023/2024. Pretoria: SAHPRA.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.